Tuesday, 25 August 2026
Solvonis Raises £1.3 Million
Solvonis Therapeutics plc
(“Solvonis” or the “Company”)
Solvonis Raises £1.3 Million to Advance Key Clinical and Regulatory Milestones
New institutional investment supports defined milestones across SVN-001, SVN-002 and SVN-015; Turner Pope appointed corporate broker
LONDON - 25 August 2026 - Solvonis Therapeutics plc (LSE: SVNS), a late clinical-stage biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders, is pleased to announce that it has conditionally raised gross proceeds of £1.3 million through a placing of 1,083,333,333 new Ordinary Shares of £0.001 each (the "Placing Shares") with new and existing investors at a placing price of £0.0012 per Placing Share (the "Issue Price") (the "Fundraising").
The Fundraising includes participation from a noted UK institutional investor as a new entrant to the Company's shareholder register.
Turner Pope Investments (TPI) Limited ("Turner Pope") acted as sole bookrunner to the Fundraising and has been appointed as the Company's corporate broker with immediate effect.
The net proceeds of the Fundraising, together with the Company's existing resources, will principally support:
· the assessment and potential addition of selected international sites, including sites in the European Union, to progress the ongoing SVN-001 Phase 3 study
· the advancement of SVN-002 towards an Investigational New Drug ("IND") submission and Phase 2b readiness in the United States; and
· the progression of SVN-015 alongside the US National Institute on Drug Abuse ("NIDA").
Anthony Tennyson, Chief Executive Officer of Solvonis, commented, "This fundraising supports clear next steps across our three priority programmes. We will assess adding selected EU sites to the SVN-001 Phase 3 study, advance SVN-002 towards US Phase 2b readiness, and progress SVN-015 alongside NIDA.
"We are also pleased to welcome a new and renowned institutional investor and to appoint Turner Pope as corporate broker following its role as sole bookrunner. The Board believes that the addition of new institutional capital is an important development as Solvonis advances its clinical and preclinical pipeline and broadens engagement with the UK investment community."
Use of Proceeds
The net proceeds of the Fundraising, together with the Company's existing resources, will principally be applied as follows.
SVN-001 - potential addition of international sites to progress Phase 3
SVN-001 is Solvonis' investigational combination treatment for severe Alcohol Use Disorder ("AUD"), comprising intravenous ketamine together with a proprietary, manualised relapse-prevention cognitive behavioural therapy.
The programme is currently being evaluated in an ongoing Phase 3 clinical study in the United Kingdom.
The Company intends to assess and, subject to the agreement of its study partners and the necessary regulatory, ethics and operational approvals, seek to add selected international sites to the study, including sites within the European Union.
The objective would be to include EU patient data within the overall Phase 3 dataset, broaden its geographic representation and potentially strengthen future regulatory submissions and commercial discussions in selected European markets.
The Fundraising will support the feasibility, regulatory and operational work required to assess and prepare for the proposed expansion.
SVN-002 - progressing towards a U.S. IND and Phase 2b readiness
SVN-002 is Solvonis' proprietary esketamine oral thin-film formulation being developed as a supervised, clinic-administered treatment for moderate-to-severe AUD in the United States.
The programme is being advanced under a planned FDA 505(b)(2) regulatory pathway, with the objective of establishing a scientific bridge to an approved intranasal esketamine reference product.
In June 2026, the Company announced positive pharmacokinetic data from its preclinical bridging study, providing important support for the proposed scientific bridge.
The Fundraising will support:
· completion of the remaining work intended to establish the scientific bridge;
· further engagement with the US Food and Drug Administration regarding the planned IND and any remaining nonclinical and toxicology requirements; and
· subject to supportive results and FDA feedback, completion of the targeted IND-enabling work and preparation of the IND submission.
The objective is to position SVN-002 for Phase 2b readiness in the United States.
SVN-015 - progression alongside NIDA
SVN-015 is Solvonis' proprietary discovery-stage compound being developed initially for stimulant use disorders, including methamphetamine and cocaine use disorders.
In August 2026, the Company announced that NIDA had selected SVN-015 to advance into further evaluation under its Addiction Treatment Discovery Program following encouraging initial cardiac ion-channel and broader off-target screening results.
The next stage is expected to include further confirmatory and in vivo studies funded and undertaken through NIDA's programme. NIDA's support does not constitute a cash grant to Solvonis, and the Company retains ownership of SVN-015 and its associated intellectual property.
The Fundraising will support Solvonis' complementary programme-management, data-assessment and development-planning activities.
General working capital
The balance of the net proceeds will be applied to meet general working capital requirements and the costs associated with delivering the programme activities described above.
Appointment of Corporate Broker
Turner Pope acted as sole bookrunner to the Fundraising and has been appointed as the Company's corporate broker with immediate effect.
Details of the Fundraising
Placing Shares
The Company is proposing to issue a total of 1,083,333,333 Placing Shares at £0.0012 per share, raising gross proceeds of £1.3 million. The Fundraising is being conducted within the Company's existing share authorities.
The Issue Price represents a discount of approximately 14 per cent. to the price of £0.0014 per existing Ordinary Share, being the Closing Price on the last trading day immediately preceding the date of this announcement.
Fee Shares
The Company has agreed to settle fees for services provided to the Company amounting to £15,000 through the issue of 10,000,000 new ordinary shares of £0.0001 each at an issue price of £0.0015 per share.
Admission and Total Voting Rights
Application will be made for the Placing Shares and Fee Shares to be admitted to trading on the Main Market of the London Stock Exchange and to listing in the FCA's Official List Equity Shares (transition) category ("Admission").
It is expected that Admission will become effective and that dealings in the Placing and Fee Shares will commence at 8.00 a.m. on or around 28 August 2026.
Following Admission, the Company's enlarged issued ordinary share capital will comprise 7,899,736,826 ordinary shares of £0.001 each. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Broker Warrants
As part of its fee arrangements with the Company, Turner Pope is being granted warrants to subscribe for 78,333,333 new Ordinary Shares at the Issue Price, in whole or in part, at any time in the 5 years from Admission (the "Broker Warrants"). The Broker Warrants are freely transferable.
Adviser Warrants
As part of a separate adviser engagement, a consultant to the Company is being granted warrants to subscribe for 30,000,000 new Ordinary Shares at the Issue Price, in whole or in part, at any time in the 5 years from Admission (the "Adviser Warrants"). The Adviser Warrants are freely transferable.
Orana Warrants
As part of its fee arrangements for the provision of its accounting services to the Company, Orana Corporate is being granted warrants to subscribe for 25,000,000 new Ordinary Shares at the Issue Price pursuant to the key terms set out below:
- Exercise period: 5 years from the date of Admission
- Vesting conditions:
(A) Vesting Event | (B) Trigger for Vesting | (C) Number of Warrants Vested on Date of Vesting |
One | On Admission | 9,000,000 Warrants |
Two | 12 months from Admission | 8,000,000 Warrants |
Three | 24 months from Admission | 8,000,000 Warrants |
Enquiries
Solvonis Therapeutics plc
Anthony Tennyson, Chief Executive Officer and Executive Director
info@solvonis.com
Turner Pope Investments (TPI) Limited
Corporate Broker and Sole Bookrunner
Andrew Thacker / Guy McDougall
+44 (0)20 3657 0050
About Solvonis Therapeutics plc
Solvonis Therapeutics plc (LSE: SVNS) is a late clinical-stage biopharmaceutical company developing small-molecule therapeutics for high-burden central nervous system (“CNS”) disorders. Headquartered in London and listed on the Main Market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and discovery-stage compounds across addiction and psychiatry.
The Company’s lead programmes target Alcohol Use Disorder (“AUD”) and Post-Traumatic Stress Disorder (“PTSD”), with additional development and discovery work supporting expansion into further addiction and psychiatric indications, including stimulant use disorder and depressive disorders.
Its lead asset, SVN-001, is currently in Phase 3 for severe AUD in the UK, while SVN-002 is being advanced towards a planned Phase 2b trial in the United States targeting moderate-to-severe AUD. The Company’s PTSD discovery programme has identified SVN-114 as a lead compound, emerging from a proprietary compound series designed to modulate key brain-signalling systems associated with emotional processing and social behaviour.
SVN-015 is the Company’s proprietary discovery-stage candidate targeting stimulant use disorder. Following encouraging initial cardiac ion-channel and broader off-target screening results, it is advancing into further preclinical evaluation under NIDA’s Addiction Treatment Discovery Program.
In parallel, Solvonis is advancing proprietary CNS discovery programmes supported by a dedicated compound library and AI-enabled discovery capabilities to identify new small-molecule modulators of key neurotransmitter systems.
